Diagnostic accuracy of osteopontin for malignant pleural mesothelioma: A systematic review and meta-analysis

Clinica Chimica Acta

Volumn 433, Issue , 2014, Pages 44-48

  Hu, Zhi De ^a   Liu, Xiao Fei ^a   Liu, Xiao Cui ^b   Ding, Chun Mei ^a   Hu, Cheng Jin ^a  

^a General Hospital of Ji'nan Military Region   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Diagnostic accuracy; Malignant pleural mesothelioma; Meta analysis; Osteopontin; Systematic review

Indexed keywords

OSTEOPONTIN; TUMOR MARKER;

ARTICLE; DATA BASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; HUMAN; INFORMATION RETRIEVAL; META ANALYSIS; METHODOLOGY; NONHUMAN; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SAMPLE SIZE; SCIENTIFIC LITERATURE; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; BLOOD; LUNG NEOPLASMS; MESOTHELIOMA;

HUMANS; LUNG NEOPLASMS; MESOTHELIOMA; OSTEOPONTIN; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84896302429     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2014.02.024     Document Type: Article

References (36)

1. Rudd R.M. Malignant mesothelioma. Br Med Bull 2010, 93:105-123.
2. Tsao A.S., Wistuba I., Roth J.A., Kindler H.L. Malignant pleural mesothelioma. J Clin Oncol 2009, 27:2081-2090.
3. Tomasetti M., Amati M., Santarelli L., Alleva R., Neuzil J. Malignant mesothelioma: Biology, diagnosis and therapeutic approaches. Curr Mol Pharmacol 2009, 2:190-206.
4. Suzuki H., Hirashima T., Kobayashi M., et al. Prognostic factors in malignant pleural mesothelioma: a retrospective study. Intern Med 2012, 51:707-710.
5. Helland A., Solberg S., Brustugun O.T. Incidence and survival of malignant pleural mesothelioma in norway: a population-based study of 1686 cases. J Thorac Oncol 2012, 7:1858-1861.
6. Kent M., Rice D., Flores R. Diagnosis, staging, and surgical treatment of malignant pleural mesothelioma. Curr Treat Options Oncol 2008, 9:158-170.
7. Ordonez N.G. Immunohistochemical diagnosis of epithelioid mesothelioma: an update. Arch Pathol Lab Med 2005, 129:1407-1414.
8. Ray M., Kindler H.L. Malignant pleural mesothelioma: an update on biomarkers and treatment. Chest 2009, 136:888-896.
9. Tomasetti M., Santarelli L. Biomarkers for early detection of malignant mesothelioma: Diagnostic and therapeutic application. Cancer 2010, 2:523-548.
10. Uede T. Osteopontin, intrinsic tissue regulator of intractable inflammatory diseases. Pathol Int 2011, 61:265-280.
11. Weber G.F. The cancer biomarker osteopontin: combination with other markers. Cancer Genomics Proteomics 2011, 8:263-288.
12. Cao D.X., Li Z.J., Jiang X.O., et al. Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers. World J Gastroenterol 2012, 18:3923-3930.
13. Whiting P.F., Rutjes A.W., Westwood M.E., et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011, 155:529-536.
14. Zamora J., Abraira V., Muriel A., Khan K., Coomarasamy A. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol 2006, 6:31.
15. Moses L.E., Shapiro D., Littenberg B. Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med 1993, 12:1293-1316.
16. Walter S.D. Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test data. Stat Med 2002, 21:1237-1256.
17. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
18. Deville W.L., Buntinx F., Bouter L.M., et al. Conducting systematic reviews of diagnostic studies: didactic guidelines. BMC Med Res Methodol 2002, 2:9.
19. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
20. Pass H.I., Lott D., Lonardo F., et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 2005, 353:1564-1573.
21. Paleari L., Rotolo N., Imperatori A., et al. Osteopontin is not a specific marker in malignant pleural mesothelioma. Int J Biol Markers 2009, 24:112-117.
22. Grigoriu B.D., Scherpereel A., Devos P., et al. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res 2007, 13:2928-2935.
23. Cristaudo A., Foddis R., Bonotti A., et al. Comparison between plasma and serum osteopontin levels: usefulness in diagnosis of epithelial malignant pleural mesothelioma. Int J Biol Markers 2010, 25:164-170.
24. Creaney J., Yeoman D., Musk A.W., de Klerk N., Skates S.J., Robinson B.W. Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma-which is best?. Lung Cancer 2011, 74:55-60.
25. Creaney J., Yeoman D., Demelker Y., et al. Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma. J Thorac Oncol 2008, 3:851-857.
26. Bossuyt P.M., Reitsma J.B., Bruns D.E., et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Clin Chem 2003, 49:7-18.
27. Cleophas T.J., Zwinderman A.H. Meta-analyses of diagnostic studies. Clin Chem Lab Med 2009, 47:1351-1354.
28. Lanteri P., Lombardi G., Colombini A., Grasso D., Banfi G. Stability of osteopontin in plasma and serum. Clin Chem Lab Med 2012, 50:1979-1984.
29. Denhardt D.T., Noda M., O'Regan A.W., Pavlin D., Berman J.S. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 2001, 107:1055-1061.
30. Hollevoet K., Reitsma J.B., Creaney J., et al. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol 2012, 30:1541-1549.
31. Qin Q., Hu Z., Deng A. Is osteopontin stable in plasma and serum?. Clin Chem Lab Med 2013, 51:e3-e4.
32. Luo L., Shi H.Z., Liang Q.L., Jiang J., Qin S.M., Deng J.M. Diagnostic value of soluble mesothelin-related peptides for malignant mesothelioma: a meta-analysis. Respir Med 2010, 104:149-156.
33. Pantazopoulos I., Boura P., Xanthos T., Syrigos K. Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma. Eur Respir J 2013, 41:706-715.
34. Cristaudo A., Bonotti A., Simonini S., et al. Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma. J Thorac Oncol 2011, 6:1587-1593.
35. Pencina M.J., D'Agostino R.B., Vasan R.S. Statistical methods for assessment of added usefulness of new biomarkers. Clin Chem Lab Med 2010, 48:1703-1711.
36. Pencina M.J., D'Agostino R.B., D'Agostino R.B., Vasan R.S. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008, 27:157-172. [discussion 207-112].